US to buy 500,000 remdesivir coronavirus treatment courses at $2,340 each

Clinical trials revealed the drug can help patients recover from the coronavirus faster.

Sean Keane Former Senior Writer
Sean knows far too much about Marvel, DC and Star Wars, and poured this knowledge into recaps and explainers on CNET. He also worked on breaking news, with a passion for tech, video game and culture.
Expertise Culture | Video Games | Breaking News
Sean Keane
2 min read
Vial of remdesivir

A five-day remdesivir treatment course will cost $2,340, drugmaker Gilead Sciences said.

Ulrich Perrey/Pool/AFP via Getty Images

The US Department of Health and Human Services has agreed to buy 500,000 remdesivir treatment courses, in the wake of clinical trials revealing the drug can help patients recover more quickly from the coronavirus. A five-day course will cost $2,340,or $3,120 for commercially insured patients, biotech firm Gilead Sciences said.

Early last month, the Food and Drug Administration issued an emergency authorization for remdesivir to be used in cases of  COVID-19 when patients were "hospitalized with severe disease," shortly after the drug showed "clear-cut positive effect" in a US trial. 

"To the extent possible, we want to ensure that any American patient who needs remdesivir can get it," HHS Secretary Alex Azar said in a release.

Read more: Coronavirus treatments: Remdesivir, hydroxychloroquine and vaccines for COVID-19

It comes a day after the total number of confirmed cases crossed 10 million globally, with 500,000 deaths, according to the Johns Hopkins COVID-19 database. As of early Monday, the US had more than 2.5 million confirmed cases, with over 125,000 deaths and 685,000 recoveries.

Fighting coronavirus: COVID-19 tests, vaccine research, masks, ventilators and more

See all photos

Gilead CEO Daniel O'Day addressed the higher price for private insurers, according to health site Stat, by noting that there are "always two prices" for a drug in the US. In an open letter, he acknowledged that the company's work on remdesivir is "far from done."

"We continue to explore its potential to help in this pandemic in various ways, such as evaluating treatment earlier in the course of the disease, in outpatient settings, with an inhaled formulation, in additional patient groups and in combination with other therapies," he wrote.

He also said that countries in the developing world will get the drug at greatly reduced prices, through generic manufacturers.

Watch this: Coronavirus drug shows 'clear-cut' evidence of faster recovery, Dr. Fauci says
The information contained in this article is for educational and informational purposes only and is not intended as health or medical advice. Always consult a physician or other qualified health provider regarding any questions you may have about a medical condition or health objectives.